BioPharma: Problems mount as directors resign from LumiraDx
The outlook for BioPharma Credit's biggest loan deteriorates as three founders of LumiraDx jump ship from the struggling US diagnostics firm faced with delisting from Nasdaq.
Investment company news brought to you by Citywire Financial Publishers Limited and Quoted Data by Marten & Co.
Schiehallion snaps up its shares as discount widens to over 55%
The £880m Baillie Gifford pre-flotation ‘unicorn’ fund launches a $20m (£16.4m) share buyback programme after a drastic de-rating halves the stock price this year.
ThomasLloyd Energy rebrands as new manager warns of losses
Transitional manager Octopus Energy Generation said the newly named Asian Energy Impact Trust is likely to incur losses of more than the estimated £13m.
Discounted India Capital Growth launches £5m buyback
India Capital Growth, which trades on a double-digit discount, has announced it will repurchase shares up to a maximum of £5m.
Sub-scale and uneconomic: Chelverton Growth plans wind-down
Minnow trust Chelverton Growth is planning a wind-down after global economic events scuppered shareholder returns.
US Solar: Investors must sign off wider investment policy to finalise Amber appointment
Changes include allowing the manager to invest up to 15% in late-stage development assets.
US Solar: Investors must approve changes to seal Amber’s appointment
Changes include allowing the manager to invest up to 15% in late-stage development assets.
RTW Biotech swoops on former Woodford darling Arix Bioscience
RTW Biotech Opportunities buys the assets of rival Arix Bioscience in an all-share deal that will boost its portfolio by two thirds to £452m.
‘Unusual’ October sees two trusts take secondary listings
Primary Health Properties and Aquila European Renewables recently listed on a second stock exchange joining 15 other UK investment trusts that make their shares accessible internationally.
Capital Gearing blames court delays for three-month drop in buybacks
Shares in £1bn wealth preservation fund slip to their widest discount for a year after warning it was running out of cash for buybacks, provoking a downgrade by analysts at its broker, JPMorgan Cazenove.
Oakley's discount behind the pack despite solid quarter
The private equity fund, which is shortlisted for a Citywire award, delivered a 2.5% total return, driven by portfolio growth and foreign exchange gains, but the shares' 38% discount remains wider than the 30% sector average.
Jupiter sells down Chrysalis stake as recovery reverses
Jupiter has sold down its stake in its Chrysalis fund as the value has slipped back over the past quarter.
